What's Hot in Clots: March 2025

It’s hard to stay focused with news that may markedly impact the direction of research but I’m trying to distract myself! Here are the updates for the month:

Anticoagulation with or without aspirin after caval / iliofemoral stenting for post-thrombotic syndrome

Endovascular procedures are an option in patients with post-thrombotic syndrome and caval or iliofemral residual DVTs. However, it’s not known what the best course of antithrombotic therapy procedurally would be.

Results from a recent RCT, albeit not definitive, suggest that anticoagulation alone is likely sufficient. Read more.

Subsegmental PE: More uncertainty than answers

I get it, many of us are clinicians. So, let me state at the outset that we don’t yet know which patients with isolated subsegmental PE should be treated. But the problem is even bigger than that.

A recent study not only re-emphasized the variations in individual radiologists’ reads compared with an organized core laboratory of experts, but also showed that the specific codes for subsegmental PE are notoriously inaccurate. Read more.

DOACs for cerebral venous sinus thrombosis

Short of an RCT, this study provides additional empiric evidence about the risk of thrombotic and hemorrhagic events with DOACs for treatment of cerebral venous sinus thrombosis (CVST). Read more. Want more on CVST? Okay!

This study found a higher incidence of new cancer diagnosis compared with controls. Read more.

CABG after receiving ticagrelor: How long of a wait time is long enough?

I was always skeptical that one really needed several days prior to consideration of a coronary artery bypass graft (CABG) once patients received P2Y12 inhibitors. A recent—and interesting—non-inferiority trial put it to the test.

CABG being done early (median 3 days) vs late (median 6 days) after exposure to ticagrelor for acute coronary syndrome was non-inferior with respect to serious perioperative bleeding. Read more.